{"nctId":"NCT01483144","briefTitle":"Trial of Eflornithine Plus Sulindac in Patients With Familial Adenomatous Polyposis (FAP)","startDateStruct":{"date":"2013-10"},"conditions":["Familial Adenomatous Polyposis"],"count":171,"armGroups":[{"label":"Eflornithine plus Sulindac","type":"EXPERIMENTAL","interventionNames":["Drug: Eflornithine","Drug: Sulindac 150 MG"]},{"label":"Eflornithine plus Sulindac Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Eflornithine","Drug: Sulindac placebo"]},{"label":"Sulindac plus Eflornithine Placebo","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Eflornithine Placebo","Drug: Sulindac 150 MG"]}],"interventions":[{"name":"Eflornithine","otherNames":["CPP-1X"]},{"name":"Eflornithine Placebo","otherNames":["CPP-1X placebo"]},{"name":"Sulindac 150 MG","otherNames":["Clinoril"]},{"name":"Sulindac placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of phenotypic classical FAP with disease involvement of the duodenum and/or colon/rectum/pouch.\n\n  1. Genotype: Adenomatous polyposis coli (APC) mutation (with or without family history) required\n  2. Classical FAP Phenotype: 100's to 1,000's of colorectal adenomatous polyps, usually appearing in teenage years\n* Upper gastrointestinal (UGI) endoscopy/ lower gastrointestinal (LGI) endoscopy (proctoscopy/colonoscopy) performed within 30 days of randomization.\n* Patients with an intact colon/rectum, except for clinical polyposis, and prophylactic surgery is being considered as a stratification site.\n* Rectal/pouch polyposis as a stratification site as follows:\n\n  1. At least three years since colectomy with ileorectal anastamosis (IRA)/proctocolectomy with pouch, and demonstrating polyposis as defined by Stage 1, 2, 3, of the proposed InSiGHT 2011 Staging System (Appendix B) and summarized as follows:\n\n     Stage 1: 10-25 polyps, all \\< 5 mm Stage 2: 10-25 polyps, at least one \\> 1 cm Stage 3: \\>25 polyps amenable to complete removal, or any incompletely removed sessile polyp, or any evidence of high grade dysplasia, even if completely removed. \\[Note: For staging purposes only.\\]\n  2. For all subjects, any rectal/pouch polyps \\> 5 mm must be excised at \"baseline\".\n* Duodenal polyposis as a stratification site; one or more of the following:\n\n  1. Current Spigelman Stage 3 or 4.\n  2. Prior surgical endoscopic intervention within the past six months for Spigelman Stage 3 or 4 that may have been down staged to Spigelman Stage 1 or 2.\n* Hematopoietic Status (within 30 days prior to randomization):\n\n  1. No significant hematologic abnormalities\n  2. White blood cell count (WBC) at least 3,000/mm3\n  3. Platelet count at least 100,000/mm3\n  4. Hemoglobin at least 10.0 g/dL\n  5. No history of clinical coagulopathy\n* Hepatic Status (within 30 days prior to randomization):\n\n  1. Bilirubin no greater than 1.5 times ULN\n  2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times ULN\n  3. Alkaline phosphatase no greater than 1.5 times ULN\n* Renal Status (within 30 days prior to randomization):\n\n  a) Creatinine no greater than 1.5 times ULN\n* Hearing:\n\n  a) No clinically significant hearing loss, defined in Section 6.2, number 9.\n* If female, neither pregnant nor lactating.\n* Negative pregnancy test if female of child-bearing potential. Fertile patients must use effective contraception\\*.\n* Absence of gross blood in stool; red blood on toilet paper only acceptable.\n* No discrete gastric or duodenal ulcer greater than 5 mm within the past year except Helicobacter pylori-related peptic ulcer disease treated with antibiotics.\n* No invasive malignancy within the past 5 years except resected non-melanomatous skin cancer, papillary thyroid cancer, or precancerous cervical dysplasia.\n* No other significant medical or psychiatric problems that would preclude study participation or interfere with capacity to give informed consent.\n* Use of 81-100 mg daily aspirin or up to 700 mg aspirin not more than once a week are eligible.\n* No concurrent warfarin, fluconazole, lithium, Pradaxa® or other direct thrombin inhibitors, Plavix®, cyclosporine, other NSAIDs (such as ibuprofen, aspirin, diflunisal), diuretics (furosemide and thiazides), dimethylsulfoxide (DMSO), methotrexate, probenecid, propoxyphene hydrochloride, Tylenol® (acetaminophen) preparations containing aspirin or cytotoxic chemotherapy drugs.\n* Willingness to forego concurrent use of supplements containing omega-3 fatty acids, corticosteroids, non-steroidal anti-inflammatory drugs or other FAP directed drug therapy.\n* Able to provide informed consent and follow protocol requirements.\n\nExclusion Criteria:\n\n* Prior pelvic irradiation.\n* Patients receiving oral corticosteroids within 30 days of enrollment.\n* Treatment with other investigational agents in the prior 4 weeks.\n* Use of other non-steroidal anti-inflammatory drugs (such as ibuprofen) exceeding 4 days per month, in the prior 6 weeks.\n* Regular use of aspirin in excess of 700 mg per week.\n* Treatment with other FAP directed drug therapy (including sulindac or celecoxib, fish oil) within 12 weeks of study enrollment.\n* Hypersensitivity to cyclooxygenase-2 inhibitors, sulfonamides, NSAIDs, or salicylates; NSAID associated symptoms of gastritis.\n* Patients must not have cardiovascular disease risk factors as defined below:\n\n  * Uncontrolled high blood pressure (systolic blood pressure \\> 150 mm Hg\n  * Unstable angina\n  * History of documented myocardial infarction or cerebrovascular accident\n  * New York Heart Association Class III or IV heart failure\n  * Known uncontrolled hyperlipidemia defined as LDL-C \\>= 190 mg/dL or triglycerides \\>= 500 mg/dL\n* Patients with significant hearing loss are not eligible for study participation defined as hearing loss that affects everyday life and/or for which a hearing aid is required.\n* Colon/rectum/pouch with high grade dysplasia or cancer on biopsy or a large polyp (\\>1 cm) not amenable to complete removal.\n* Duodenal cancer on biopsy.\n* Intra-abdominal desmoid disease, stage III or IV\n* Inability to provide informed consent.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Subjects With Any FAP-related Event.","description":"Progression of disease by evaluation of FAP-related events over the course of study treatment","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"23","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement in Investigator Upper GI Assessment","description":"Global assessment of change in upper GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null},{"groupId":"OG001","value":"10","spread":null},{"groupId":"OG002","value":"10","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"47","spread":null},{"groupId":"OG002","value":"48","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement in Investigator Lower GI Assessment","description":"Global assessment of change in lower GI polyp burden. These are binary outcomes derived from scores assigned by the investigator during each procedure, using a scale (-2, -1, 0, +1, +2) which corresponds, respectively, to the investigator's overall qualitative assessment of: much worse, worse, no change, improved, much improved. Summarizes the corresponding 6- and 12-month investigator change scores according to whether or not there was any positive improvement at either month 6 (compared to baseline) or at month 12 (compared to baseline or month 6), under the condition that there be no worsening at either timepoint.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22","spread":null},{"groupId":"OG001","value":"16","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"41","spread":null},{"groupId":"OG002","value":"36","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":11,"n":56},"commonTop":["nausea","headache","vomiting","diarrhoea","abdominal pain"]}}}